Breast cancer metastasis

Show results for

Unknown (11132)
Genomics (2066)
Transcriptomics (1703)
Proteomics (252)
Other (56)
Clinical (48)
Methylation profiling (28)
Metabolomics (24)
Genomic (5)
Models (4)

Organisms

Homo sapiens (1690)
Mus musculus (661)
Rattus norvegicus (12)
Canis lupus familiaris (11)
synthetic construct (10)
Danio rerio (2)
Nesolagus netscheri (2)
Capra hircus (1)
Gallus gallus (1)
Drosophila melanogaster (1)
Betapolyomavirus hominis (1)
Betapolyomavirus macacae (1)
Fusobacterium nucleatum (1)
Homo (1)
Human alphaherpesvirus 1 (1)
Human betaherpesvirus 5 (1)
Human gammaherpesvirus 8 (1)
Human immunodeficiency virus 1 (1)
JC polyomavirus (1)
Macaca mulatta (1)
Murid betaherpesvirus 1 (1)
Murid gammaherpesvirus 4 (1)
Mus (1)
human gammaherpesvirus 4 (1)
cellular organisms (1)

Organisms

Homo sapiens (1007)
Mus musculus (461)
Canis lupus familiaris (5)
Rattus norvegicus (4)
Fusobacterium nucleatum (1)
human saliva metagenome (1)
Homo (1)
Mammalia (1)
Mus (1)
Macaca mulatta (1)
Danio rerio (1)

Repository

ENA (1738)
geo (1481)
biostudies-arrayexpress (545)
pride (185)
EGA (82)
iProX (32)
MassIVE (27)
MetaboLights (22)
ExpressionAtlas (5)
dbGaP (5)
jPOST (5)
BioModels (4)
GPMDB (3)
GNPS (1)
MetabolomicsWorkbench (1)
NODE (1)
PanoramaPublic (1)

Tissue

Cell culture (88)
Epithelial cell (54)
Breast (16)
Permanent cell line cell (16)
Lung (6)
Lymph node (5)
Blood (5)
Mammary gland epithelial cell (5)
Breast cancer cell line (4)
Blood plasma (3)
Brain (3)
Breast cancer cell (3)
Fibroblast (3)
Mammary gland (3)
Blood serum (2)
Culture fluid (2)
Liver (2)
Primary cell (2)
Stem cell (2)
Adipose tissue (1)
Basophil (1)
Blood cell (1)
Blood-brain barrier (1)
Breast cancer stem cell (1)
Breast cell line (1)
Breast epithelium (1)
Breast invasive ductal carcinoma cell (1)
Cell suspension culture (1)
Cerebral cortex (1)
Cerebral cortex endothelial cell (1)

Disease

Breast adenocarcinoma (3)
Glioblastoma (2)
Melanoma (2)
AIDs related Burkitts lymphoma (1)
Acute lymphoblastic (T-ALL) leukemia (1)
Acute lymphoblastic leukemia (1)
Adenocarcinoma HER2/ERBB2 transfectant of MDA-MB-435 melanoma (1)
Adenocarcinoma of colon (1)
Adenocarcinoma of lung (1)
Adenocarcinoma of prostate (1)
Adenocarcinoma prostate PC-3 subline isolated from liver metastasis in mice (1)
Adenocarcinoma, breast grown from mouse mammary fat pad (1)
Anaplastic astrocytoma (1)
Carcinoma, renal cell (1)
Cervical adenocarcinoma (1)
Chronic myelogenous (blast crisis) leukemia (1)
Colon carcinoma (1)
Gastric adenocarcinoma (1)
Hepatocellular carcinoma (1)
Large cell lung carcinoma (1)
Large cell undifferentiated lung (1)
Lung metastasis (1)
Lymphoblastic Burkitt's lymphoma (1)
Malignant amelanocytic melanoma (1)
Malignant melanoma (1)
Metastatic malignant melanoma (1)
Non-small cell lung carcinoma (1)
Ovarian adenocarcinoma (1)
Ovarian carcinoma (1)
Pancreatic adenocarcinoma (1)

Technology Type

Mass Spectrometry (186)
Shotgun proteomics (105)
Bottom-up proteomics (32)
Affinity purification coupled with mass spectrometry proteomics (19)
Data-dependent acquisition (16)
Mass spectrometry assay (11)
SWATH MS (11)
Gel-based experiment (10)
Data-independent acquisition (9)
Mass spectrometry (8)
Illumina HiSeq 2000 (4)
NMR spectroscopy (3)
Illumina HiSeq 2500, ILLUMINA (2)
Illumina HiSeq 2000, Illumina MiSeq, ILLUMINA, Illumina HiSeq 2500 (2)
Illumina HiSeq 2000, Illumina MiSeq (2)
Illumina HiSeq 2500, ILLUMINA, Illumina MiSeq, Illumina HiSeq 2000 (2)
SRM/MRM (2)
Top-down proteomics (2)
Illumina HumanWG-6 (1)
Illumina HiSeq 2500, Illumina HiSeq 4000, ILLUMINA, NextSeq 500 (1)
Illumina MiSeq, ILLUMINA (1)
Illumina HiSeq 2500 (ILLUMINA) (1)
Illumina HiSeq 2000, ILLUMINA, Illumina HiSeq 2500 (1)
Illumina Genome Analyzer II, Illumina HiSeq 2000, ILLUMINA (1)
Illumina HiSeq 2000, Illumina Genome Analyzer II (1)
Illumina Genome Analyzer II, Illumina HiSeq 2000 (1)
Illumina HiSeq 2000, Illumina Genome Analyzer II, ILLUMINA (1)
Illumina Genome Analyzer II (1)
ESI (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (11)
Q Exactive Plus (8)
Q Exactive (8)
Illumina HiSeq 2500 (7)
NextSeq 500 (5)
Orbitrap Fusion Lumos (4)
Liquid Chromatography MS - positive - reverse phase (4)
Illumina HiSeq 4000 (3)
Instrument (3)
Illumina HiSeq 2000 (2)
LTQ Orbitrap (2)
LTQ Orbitrap Velos (2)
Orbitrap Fusion (2)
Agilent Bioanalyzer 2100 (or TapeStation); Qubit 4 Fluorometer (Thermo Fisher Scientific) (1)
NanoDrop ND-1000 spectrophotometer (1)
10X Genomics Chromium v3.1 with multiplexing kit (1)
Affymetrix (1)
Ion Torrent Proton (1)
NextSeq 2000 (1)
DNBSEQ-G400 (1)
DNBSEQ-T7 (1)
HiSeq X Ten (1)
Illumina MiSeq (1)
7000A Triple Quadrupole GC/MS (1)
Orbitrap Eclipse (1)
Orbitrap Exploris 480 (1)
Q Exactive HF-X (1)
Q-Exactive Plus (1)
QExactive Plus (1)
TimsTOF Pro 2 (1)

Publication Date

2025 (236)
2026 (199)
2023 (184)
2024 (183)
2022 (160)
2014 (150)
2013 (139)
2021 (121)
2016 (120)
2020 (120)
2015 (101)
2012 (96)
2019 (87)
2018 (76)
2017 (70)
2010 (69)
2011 (68)
2009 (47)
2008 (35)
2007 (23)
2006 (10)
2005 (10)
2003 (1)
2002 (1)

CHEBI ID

CHEBI:15428 (6)
CHEBI:16335 (5)
CHEBI:7916 (5)
CHEBI:27897 (5)
CHEBI:26271 (5)
CHEBI:16811 (5)
CHEBI:25017 (5)
CHEBI:32816 (5)
CHEBI:25094 (4)
CHEBI:22653 (4)
CHEBI:17200 (4)
CHEBI:17821 (4)
CHEBI:16958 (4)
CHEBI:30915 (4)
CHEBI:16704 (4)
CHEBI:16708 (4)
CHEBI:17154 (4)
CHEBI:17368 (4)
CHEBI:30769 (4)
CHEBI:16797 (4)
CHEBI:16919 (4)
CHEBI:17750 (4)
CHEBI:24898 (4)
CHEBI:15354 (4)
CHEBI:27266 (4)
CHEBI:16628 (3)
CHEBI:16010 (3)
CHEBI:85299 (3)
CHEBI:49033 (3)
CHEBI:18237 (3)

Metabolite Name

Myo-Inositol (7)
Glycine (7)
Adenine (6)
Guanine (6)
Adenosine (6)
3-phosphoglycerate (6)
Beta-alanine (6)
2-hydroxyglutarate (5)
Guanosine (5)
ATP (5)
AMP (5)
Pyridoxine (5)
Xanthine (5)
ADP (5)
UDP-glucose (5)
Pyruvate (5)
XMP (4)
DCTP (4)
DATP (4)
S-methylcysteine (4)
N6-acetyllysine (4)
N-acetylphenylalanine (4)
3-methyl-2-oxobutyrate (4)
6-phosphogluconate (4)
UDP-galactose (4)
Carnitine (4)
Urate (4)
Citrate (4)
N-acetylcysteine (4)
N-acetylmethionine (4)

First Public Date

2014 (255)
2024 (219)
2025 (206)
2026 (196)
2023 (189)
2022 (143)
2020 (112)
2021 (96)
2019 (90)
2017 (60)
2018 (58)
2015 (49)
2016 (41)
2013 (24)

Modelling Approach

Ordinary differential equation model (2)
Computational model (1)

Study status

Completed (21)
Recruiting (11)
Terminated (5)
Withdrawn (3)
Suspended (2)
Not yet recruiting (2)
Not provided (2)
Ongoing (1)
Active, not recruiting (1)

Lab affiliation

Masaryk University, Faculty of Science (4)
Department of Biochemistry and Molecular Biology & The Center for Systems Biology University of Iceland Sturlugata 8, 101 Reykjavik Iceland. (3)
Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe-Universität, Frankfurt am Main, Germany (3)
Assistant Professor, Departments of Oncology & Pathology, McGill University Principal Investigator, Cancer Research Program, MUHC-RI 1001 Decarie Blvd, EM2.2218 514.934.1934 ext 76307 Montréal, Canada (2)
CRCI2NA, Nantes University, INSERM, CNRS, Université d’Angers, Nantes, France. (2)
CRUK Beatson Institute (2)
Centro de Investigación Príncipe Felipe, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain (2)
Department of Biochemistry and Molecular Biology. Institut Universitari de Biotecnologia i Biomedicina. Universitat de València, València. Spain (2)
Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan, 44919, Republic of Korea (2)
Department of Chemistry and Biomolecular Sciences, University of Ottawa, Canada (2)
Tufts University (2)
University of Alabama at Birmingham, Department of Pathology, Division MCP, O'Neal Comprehensive Cancer Center (2)
1 Garvan Institute of Medical Research and The Kinghorn Cancer Centre, 384 Victoria Street Darlinghurst Sydney, NSW, 2010, Australia. 2 St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Australia. (1)
1) Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia. 2) Discipline of Biochemistry, School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia. 3) Department of Medicine, University of Adelaide, Adelaide, Australia. (1)
1) Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States 2) Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States (1)
1. Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands 2. Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, The Netherlands (1)
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (1)
Associate Professor of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN (1)
Baylor College of Medicine (1)
BioOrganic Mass Spectrometry laboratory (LSMBO) Institut Plurisciplinaire Hubert Curien University of Strasbourg. France (1)
Bioheat and mass transfer laboratory, Med-X Research Institute, Shanghai Jiao Tong University (1)
Biotech Research & Innovation Center (BRIC), University of Copenhagen, Denmark (1)
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark. (1)
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), DK-2200 Copenhagen, Denmark (1)
Biozentrum, University of Basel, Switzerland (1)
Boston University School of Medicine (1)
CRCM, Cell Polarity, Cell signalling and Cancer “Equipe labellisée Ligue Contre le Cancer”, Inserm,U1068, Marseille, F-13009, France Institut Paoli-Calmettes, Marseille, F-13009, France Aix-Marseille Université, F-13284, Marseille, France CNRS, UMR7258 (1)
CRG, UPF (1)
CRUK - Beatson Institute for Cancer Research - Switchback Rd, Bearsden, Glasgow G61 1BD - United Kingdom (1)
Cancer Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia (1)

Keyword

Immunotherapy (5)
Cyclophosphamide (4)
Albumin-Bound Paclitaxel (3)
Gemcitabine (3)
Pembrolizumab (3)
Liver metastases (3)
Cetuximab (3)
Breast (2)
Checkpoint Inhibitor (2)
Adult primary hepatocellular carcinoma (2)
Gastrointestinal stromal tumor (2)
Liver Cancer (2)
Fludarabine (2)
Lung (2)
Liver (2)
Pancreas cancer (2)
Carcinoembryonic antigen (2)
CAR-T (2)
Carboplatin (2)
Kidney cancer (2)
Liver Metastases (2)
Metastatic cancer (2)
Recurrent cancer (2)
Atezolizumab (2)
Pancreatic (2)
Phase 1 (2)
Radiosurgery (2)
Stage IV gastric cancer (2)
Stage IV breast cancer (2)
Stage IV ovarian epithelial cancer (2)

IsPrivate

False (4)

Submitter Keywords

FAIR-AIML (1)
Immuno-oncology (1)

Classification

bacteria (1)

Modification

2x(15)N labeled L-lysine (1)
4x(15)N labeled L-arginine (1)

Study type

Transcription profiling by array (401)
Interventional (43)
RNA-seq of coding RNA (41)
Comparative genomic hybridization by array (22)
ChIP-seq (18)
Unknown experiment type (11)
MicroRNA profiling by array (6)
Methylation profiling by array (6)
RNA-seq of total RNA (6)
RNA-seq of coding RNA from single cells (5)
RNA-seq of non coding RNA (5)
ChIP-chip by tiling array (4)
Transcription profiling by RT-PCR (3)
Other (3)
Methylation profiling by high throughput sequencing (3)
Observational (3)
ChIP-chip by array (2)
Genotyping by array (2)
DNA-seq (2)
Animal - One-color microarray (1)
Cell line - One-color microarray (1)
RNAi profiling by array (1)
ATAC-seq (1)
ScATAC-seq (1)
Other (1)
Observational patient registry (1)

Release Date

2022 (1209)
2021 (1134)
2023 (1118)
2025 (1043)
2020 (1025)
2024 (888)
2019 (773)
2016 (737)
2018 (624)
2017 (615)
2015 (530)
2014 (498)
2013 (355)
2012 (294)
2011 (192)
2010 (176)
2026 (127)
2009 (127)
2008 (75)
2007 (40)
2006 (40)
2005 (27)
2004 (11)
2003 (8)
2002 (3)
2001 (2)
1998 (2)
1999 (1)

Location

United States (33)
France (6)
Spain (5)
Canada (5)
Germany (4)
Belgium (4)
United Kingdom (4)
Denmark (3)
Netherlands (2)
Australia (2)
Norway (1)
Saudi Arabia (1)
Taiwan (1)
Croatia (1)
Portugal (1)
China (1)
Poland (1)
Israel (1)
Austria (1)
Switzerland (1)
Sweden (1)

Previous page
1 / 1532
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 1532
Next page

Sort by:

Relevance

Page size

Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer

Bone metastasis is a lethal consequence of breast cancer. AT-rich interaction domain 1A gene (ARID1A), a subunit of the switch/sucrose non-fermentable (SWI/SNF) complex, regulates immunosuppressive tumor microenvironment. ARID1A deficient triple negative breast cancer promotes bone metastasis.To ...

2026-03-24 | MTBLS12768 | MetaboLights

1H-NMR metabolomics identifies hypoxanthine as a novel metastasis-associated metabolite

Breast cancer is one of the leading causes of death in females, mainly because of metastasis. Oncometabolites, produced via metabolic reprogramming, can influence metastatic signaling cascades. Accordingly, and based on our previous results, we hypothesized that metabolites from highly metastatic br...

2025-09-19 | MTBLS7764 | MetaboLights

Metabolomics revealed the influence of breast cancer on lymphatic endothelial cell metabolism, metabolic crosstalk, and lymphangiogenic signaling in co-culture

Breast cancer metastasis occurs via blood and lymphatic vessels. Breast cancer cells 'educate' lymphatic endothelial cells (LECs) to support tumor vascularization and growth. However, despite known metabolic alterations in breast cancer, it remains unclear how lymphatic endothelial cell metabolis...

2024-06-25 | MTBLS859 | MetaboLights

Adipocyte-specific Zeb1 confers breast cancer progression by triggering the tumor-associated adipose microenvironment remodeling_Lipidomics_amino

Upon penetrating the basement membrane, breast cancer cells directly interact with their surrounding adipose tissue, which forms a unique tumor-associated adipose microenvironment (TAME). However, the underlying mechanism involved in the regulation of lipid metabolic remodeling in the TAME remain...

2025-04-30 | MTBLS12287 | MetaboLights

Adipocyte-specific Zeb1 confers breast cancer progression by triggering the tumor-associated adipose microenvironment remodeling

2025-04-30 | MTBLS12286 | MetaboLights

Adipocyte-specific Zeb1 confers breast cancer progression by triggering the tumor-associated adipose microenvironment remodeling

2025-04-30 | MTBLS12405 | MetaboLights

Adipocyte-specific Zeb1 confers breast cancer progression by triggering the tumor-associated adipose microenvironment remodeling_untargeted metabolites_Lipidomics

2025-04-30 | MTBLS12289 | MetaboLights

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...

2023-06-27 | MTBLS3342 | MetaboLights

Adipocyte-specific Zeb1 confers breast cancer progression by triggering the tumor-associated adipose microenvironment remodeling_Medium and long chain fatty acids

2025-04-30 | MTBLS12290 | MetaboLights

Adipocyte-specific Zeb1 confers breast cancer progression by triggering the tumor-associated adipose microenvironment remodeling_Medium and long chain fatty acids_four group

2025-04-30 | MTBLS12291 | MetaboLights

Previous page
1 / 1532
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 1532
Next page

Sort by:

Relevance

Page size

15318 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Modification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets